The pitch sounds almost too good: AI agents that can handle millions of patient interactions—in more than 100 languages, no less—without a single safety incident. But Amigo, a New York-based startup just two years into its life, is betting that healthcare providers are ready to believe.
The company announced an $11 million Series A round led by Madrona, with participation from Optum Ventures, bringing total capital raised to $17 million. More striking, perhaps: Amigo is already in discussions to raise a Series B of $30 million to $50 million before year's end, according to Axios Pro. That accelerated fundraising timeline—unusual even in a capital-hungry sector—reflects both the company's early traction and the broader frenzy around clinical automation.
Founded in 2023 by Ali Khokhar and John Xing, Amigo builds AI agents designed to handle the tedious, error-prone work of patient intake, triage, and care navigation. The agents integrate directly with major electronic health record systems—Epic, Oracle Health, Athenahealth—and operate across what the company describes as a "trust and safety layer" meant to catch problems before they reach patients.
That safety claim matters, particularly in an industry where algorithmic mistakes can have life-or-death consequences. Amigo says its agents have processed over 3 million patient encounters in the six months prior to the funding announcement, with zero reported safety incidents. The company credits what it calls "Digital Residency," a simulation framework that puts agents through millions of adversarial test scenarios before they ever interact with real patients.
Whether that testing regime proves sufficient at larger scale remains an open question. But early customers appear willing to take the bet. Eucalyptus, a global telehealth network, signed a multi-year partnership with Amigo on July 28, 2025. Diverge Health and The Care Clinic have also signed on. And in a sign of institutional credibility, Amigo recently named Dr. Jay Shah—Chief of the Medical Staff at Stanford Health Care—as its Chief Medical Advisor.
"Amigo is addressing one of the hardest problems in healthcare AI," said Sabrina Albert, a partner at Madrona, in the company's announcement. Hard, certainly. Also lucrative, if the competitive landscape is any indication.
The healthcare AI infrastructure category has become a magnet for venture capital over the past year. Hippocratic AI raised a $141 million Series B in January 2025 at a $1.64 billion valuation, followed by a $126 million Series C at a $3.5 billion valuation. Ambience Healthcare pulled in $243 million. Abridge closed a $250 million Series D. Collectively, the sector has absorbed hundreds of millions in fresh capital, with investors betting that clinical workflow automation will become as foundational as the EHR systems it's meant to augment.
Amigo's seed round—$6.3 million co-led by General Catalyst and GSV Ventures in November 2024, with participation from Comma Capital and Coho Deeptech—looks almost quaint by comparison. But the company's emphasis on multilingual support and deep EHR interoperability may give it an edge as policy tailwinds build. The Centers for Medicare & Medicaid Services' new ACCESS Model, a 10-year voluntary payment program supporting tech-enabled chronic care, begins its first performance period in July 2026. Meanwhile, the World Health Organization projects a global healthcare workforce shortfall approaching 11 million by 2030—a gap that has accelerated interest in automation tools that can safely handle routine clinical tasks.
Amigo maintains HIPAA, SOC 2 Type II, and GDPR compliance. The company operates from New York with a team size listed on LinkedIn in the range of 11 to 50 employees, though exact headcount figures weren't disclosed.
If the rumored Series B materializes as quickly as Axios Pro suggests, Amigo will have raised upwards of $60 million in under two years—a pace that speaks either to genuine product-market fit or to investor impatience in a crowded field. Likely some of both.
